BridgeBio BBP-418 shows cardiac biomarker normalisation in LGMD2I/R9
BridgeBio Pharma has presented exploratory cardiac data from the 12-month interim analysis of FORTIFY, its Phase 3 trial of oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), showing the candidate normalised key cardiac biomarkers in treated patients to a statistically significant degree. The findings were delivered as an oral presentation at the 31st World Muscle Society Congress in Hiroshima by Volker Straub of Newcastle University.
Among participants who entered the trial with elevated high-sensitivity troponin I, a blood marker of heart muscle injury, all of those receiving BBP-418 returned to normal range by Month 12, compared with 40% in the placebo arm (p=0.0248). The least-squares mean difference in troponin I change was -17.8 ng/L (95% CI: -35.1 to -0.5; p=0.0443). A secondary cardiac finding showed 54% of BBP-418-treated participants had stable or improved left ventricular ejection fraction at Month 12, against 25% on placebo (p=0.0262). Cardiomyopathy affects around 30% of those with the L276I LGMD2I/R9 genotype, and is progressive, with an annual LVEF loss of approximately 0.4%.
Biomarker normalisation as a disease-modification signal
Separate data presented at the same congress quantified alpha-dystroglycan (αDG) glycosylation in 34 asymptomatic heterozygous FKRP carriers, establishing a reference level associated with normal muscle function at around 34% of healthy controls. In the FORTIFY cohort, BBP-418 increased mean glycosylated αDG to above carrier levels by Month 12, suggesting the therapy can restore a key downstream target to a functionally relevant threshold.
Straub noted the consistency of findings across multiple systems. "High-sensitivity troponin I fell and, in those who entered the study with elevated levels, it normalized; ejection fraction stabilized; and this happened alongside walking farther and breathing better," he said. "It's encouraging to see that the therapeutic approach seems to work across the whole muscular system, including the heart."
BridgeBio said the pattern of biomarker normalisation, alongside functional improvement from baseline rather than mere stabilisation, supports positioning BBP-418 as a potential disease-modifying therapy. That framing carries weight in rare neuromuscular disease, where most approved and investigational agents target symptom stabilisation.
Regulatory path and competitive context
BBP-418 is under FDA Priority Review, with a PDUFA target action date of 27 November 2026. It also holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, and Orphan Drug Designation from the EMA. BridgeBio is separately pursuing an expedited European approval pathway. If approved with its Rare Pediatric Disease designation intact, the company may qualify for a Priority Review Voucher, which has recent secondary-market value in the range of $100 million or more, adding a meaningful non-dilutive financial upside to approval.
The LGMD space has historically lacked approved pharmacological options; BridgeBio is positioning BBP-418 as the first approved therapy for LGMD2I/R9 and, potentially, for any LGMD subtype. A small number of academic and biotech groups are pursuing gene-therapy approaches to related dystroglycanopathies, but none has yet reached the regulatory filing stage for LGMD2I/R9 specifically. The addressable population is approximately 7,000 patients in the US and Europe, a size that makes the orphan commercial case viable but limits the revenue ceiling compared with larger neuromuscular indications such as Duchenne muscular dystrophy.
Near-term milestones include the FDA decision in late November, European regulatory engagement, and planned initiation of paediatric studies in children under 12 in the first half of 2027. BridgeBio has also signalled intent to expand BBP-418 investigation into the related subtypes LGMD2M/R13 and LGMD2U/R20.